Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial.
Clin Transl Gastroenterol
; 15(9): e1, 2024 Sep 01.
Article
en En
| MEDLINE
| ID: mdl-39023173
ABSTRACT
INTRODUCTION:
Increasing the effectiveness of eradication therapy is an important task in gastroenterology. The aim of this study was to evaluate the efficacy and safety of postbiotic containing inactivated (nonviable) Limosilactobacillus (Lactobacillus) reuteri DSM 17648 (Pylopass) as adjuvant treatment of Helicobacter pylori eradication in patients with functional dyspepsia (FD).METHODS:
This randomized, double-blind, placebo-controlled, multicenter, parallel study included H. pylori -positive patients with FD. The postbiotic group received Pylopass 200 mg bid for 14 days in combination with eradication therapy (esomeprazole 20 mg bid + amoxicillin 1,000 mg bid + clarithromycin 500 mg bid for 14 days) and another 14 days after the completion of eradication therapy. The study was registered in the ISRCTN registry (ISRCTN20716052).RESULTS:
Eradication efficiency was 96.7% for the postbiotic group vs 86.0% for the placebo group ( P = 0.039). Both groups showed significant improvements in quality of life and reduction of most gastrointestinal symptoms with no significant differences between groups. The overall number of digestive adverse effects in the postbiotic group was lower than in the placebo group. Serious adverse effects were not registered.DISCUSSION:
The postbiotic containing inactivated L. reuteri DSM 17648 significantly improves the effectiveness of H. pylori eradication therapy in FD and decreases overall number of digestive adverse effects of this therapy.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Calidad de Vida
/
Helicobacter pylori
/
Infecciones por Helicobacter
/
Claritromicina
/
Probióticos
/
Quimioterapia Combinada
/
Dispepsia
/
Limosilactobacillus reuteri
/
Amoxicilina
/
Antibacterianos
Idioma:
En
Revista:
Cli. transl. gastroenterol
/
Clin Transl Gastroenterol
/
Clinical and translational gastroenterology
Año:
2024
Tipo del documento:
Article
País de afiliación:
Rusia
Pais de publicación:
Estados Unidos